Background
==========

The incidence rates of gastric cancer have been shown to vary widely across countries [@B1],[@B2]. The highest incidence rates are in East Asia (particularly Japan, China, Mongolia and Korea) and some parts of South America, whereas the lowest rates are in North America. Over the last quarter of a century, there has been a steady decline in the age-adjusted incidence rate of gastric cancer in Japan [@B3]-[@B5], and also in other developed countries of North America and Europe [@B4],[@B6],[@B7] (**Figure [1](#F1){ref-type="fig"}A**). These trends may be attributable to a reduced intake of foods preserved by salting or smoking, and a reduction in the prevalence of *H. pylori* infection [@B8]-[@B10] through improvements in hygiene [@B3],[@B9],[@B11]-[@B14]. However, a steady increase in the estimated number of new patients with gastric cancer has been observed in Japan with the rapid aging of society (**Figure [1](#F1){ref-type="fig"}B**) [@B15].

Under these circumstances, the oncological characteristics of stomach cancer have been changing. Namely, the increasing incidence of adenocarcinoma in the cardia has been strongly associated with the increase of obesity and gastro-esophageal reflux disease followed by the development of Barrett\'s esophagus in western countries [@B16]-[@B18]. Under the influence of lifestyle "Westernization," there are also concerns that a rapid increase of adenocarcinoma in the EGJ will become evident in the near future in East Asia [@B15],[@B19],[@B20], whereas cancer at the EGJ has remained rare [@B21]-[@B23]. As some previous reports have noted, there are distinct differences in the primary site and biologic characteristics of gastric cancer between Asian patients and those from other racial and ethnic groups [@B24]-[@B26]. Although some researchers have previously investigated differences in gastric cancer between white and black or Hispanic and non-Hispanic patients using national databases in the U.S. [@B25],[@B27],[@B28], few studies focused on the Asian population have been published recently.

This present study was conducted to delineate the near future of gastric cancer in East Asia, through comparison of the long-term trends of gastric cancer subsites between Japanese patients and the East Asian population of a national database in the U.S. Our objectives were to provide relevant information that would allow clinicians to consider suitable treatment strategies and to guide planning of clinical research.

Methods
=======

Cohort Selection
----------------

Data for Japanese patients were identified from the Gastric Cancer Database at the Cancer Institute Hospital, Tokyo, Japan (CIH-GCDB) [@B29]. The database includes entries for 19,306 consecutive patients who were treated for gastric cancer between 1946 and 2014 in the department of surgery at the institute. Patients who received only endoscopic resection or treated by the chemotherapy without any surgical interventions were originally excluded in CIH-GCDB. In addition, patients with histologically proven squamous cell carcinoma, adenosquamous carcinoma or non-epithelial tumors such as lymphoma, sarcoma and metastatic cancers from other primary neoplasms were excluded from the present analyses. Patient data were completely anonymized.

Data for patients in the U.S. were obtained from the National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) database. The SEER database is a population-based publicly available data set that has been gathering data since 1973 and represents approximately 28% of all cancer cases in the U.S. After excluding histologically proven squamous cell carcinoma, sarcoma and lymphoma, a total of 78,625 patients who were diagnosed as having gastric cancer between 1973 and 2012 were enrolled. Because the data from both the SEER registry (<http://seer.cancer.gov/>) and the CIH-GCDB [@B29] are de-identified and publicly available, no institutional review board approval was necessary for this study.

Definition of the primary site
------------------------------

There is a difference in primary tumor anatomical subsite classification between the two databases (**Supplemental Figure [1](#SM1){ref-type="supplementary-material"}**). The tumor location data in SEER are coded using the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [@B30], whereas they are coded according to the classification of the Japanese Gastric Cancer Association (JGCA) [@B31] in the CIH-GCDB, being divided anatomically into three stomach regions, i.e. the upper, middle, and lower thirds defined by the lines connecting the trisected points on the lesser and greater curvatures. In addition, the area extending 2 cm above to 2 cm below the esophago-gastric junction (EGJ) is designated the EGJ area. Tumors having their epicenter in this area are designated as EGJ carcinomas. In order to account for the different anatomical subsite classifications across databases, we treated the "cardia" as synonymous with the "EGJ", the "body and fundus" as synonymous with the "upper third and middle third" and the "antrum and pylorus" as synonymous with the lower third in the JGCA data.

Study variables
---------------

Patient-level data, including gender, age at diagnosis, ethnicity, tumor primary site or location, tumor size, TNM staging and histology were identified from each of the CIH-GCDB and SEER databases. To investigate the shifts in tumor location over time, the proportional frequencies in the CIH-GCDB were calculated every ten years, and those in the SEER every five years. As potential confounders for the primary site, patient ages, gender and body mass index (BMI) were obtained for the Japanese population. The 7^th^ edition of the American Joint Committee on Cancer (AJCC) TNM classification was used for tumor staging based on CIH-GCDB data, whereas tumor staging was made on the basis of the 6^th^ edition of the AJCC TNM staging system for part of the SEER database (from 2004 to 2012, n=18,092).

Statistical analysis
--------------------

The descriptive statistics were evaluated with reference to the patients\' backgrounds and tumor characteristics and, as necessary, continuous variables were compared using Student\'s *t* test and categorical variables by Fisher\'s exact test.

To estimate the odds ratio of adenocarcinoma occurring in the upper third of the stomach, logistic regression models were analyzed with the time period as a dependent variable and incidence of cancer in the upper third of the stomach as an independent variable. In addition, to compare time trends among white and black Americans, East Asian Americans (Japanese=4,320, Chinese=2,008 and Koreans=874) living in the US, and Japanese patients entered in the CIH-GCDB. All statistical tests were two-sided, and p values of 0.05 or less were considered to indicate statistical significance. All the analyses were performed with STATA version 11.1 (Stata Corp, College Station, TX).

Results
=======

Japanese population in the CIH-GCDB
-----------------------------------

**Table [1](#T1){ref-type="table"}** shows the characteristics of the patients and their tumors in Japan. The mean patient age was 59.0 years, and the proportion of males was 65.2%. **Figure [2](#F2){ref-type="fig"}A** shows the change over time in the proportion of tumors according to the primary site for every ten-year period from 1946 to 2014. There was a marked reduction of cancer incidence in the lower third of the stomach, whereas incidence in the upper third has been increasing steadily up to the present. The proportion of EGJ cancers was found not to have changed markedly during the observation period. On the basis of **Figure [2](#F2){ref-type="fig"}A**, we divided the study period into three parts: 1946 to 1974 as the early period, 1975 to 1994 as the middle period, and 1995 to 2014 as the late period. **Table [1](#T1){ref-type="table"}** also shows the characteristics in each group. The mean age and BMI of patients at diagnosis has been increasing over time, but there have not been any significant changes in the gender ratio, histological types or cross-sectional position. Besides, the proportion of signet-ring cell carcinoma had been increasing from early to middle period.

**Figure [2](#F2){ref-type="fig"}B** shows the changes in patient age over time, and BMI at diagnosis for each sex. Logistic regression analysis showed that gender (male), age (older), BMI (obese) and period (recent years) were significant independent risk factor for the incidence of upper third gastric cancer (**Table [2](#T2){ref-type="table"}**).

US population in the SEER database
----------------------------------

**Table [3](#T3){ref-type="table"}** shows the characteristics of the U.S. patients and their tumors. In this comparison between patients as a whole and the East Asian population, there was a significant difference only in the primary site, and there were no clear differences in the other items. In the East Asian population, the proportion of tumors in the cardia was lower (9.3%) and that of tumors in the pyloric antrum was higher (29.7%). Figure [3](#F3){ref-type="fig"} shows the trend of the primary site for each of the white, black, and East Asian populations during this period. A notable increase of tumors in the cardia was evident in the white or black population during the study period overall, but no remarkable change was evident in the East Asian population over the last 15 years.

Discussion
==========

The main results of our study are threefold. First, in Japan, the incidence of gastric cancer in the lower third (antrum or pylorus) of the stomach has been steadily decreasing up to 1985, whereas that in the upper third excluding the EGJ has been steady increasing up to the present. Second, East Asians living in the United States showed a tumor location trend distinctly different from that of patients of other races living in the U.S.; their proportion of cardia cancers has not been increasing over last 15 years, unlike the trend for white and black patients. Lastly, in the Japanese population, older age, obesity, male gender and recent year of diagnosis were significant independent risk factors for upper third gastric cancer.

Whereas the incidence rate of a lot of malignant neoplasms has been rising in developed countries, these of gastric, hepatic or uterine cervix cancer showed decline tendency [@B1],[@B2],[@B6],[@B7]. The principal reason has been thought to be attributed to improvements in general public health. Namely the etiology these neoplasms were strongly associated to prevalence of specific virus or bacterial infection, and the decreasing of incident rate and advances of hygienic environment were observed in developed countries. Among environmental factors associated with the risk of gastric cancer, some researchers have regarded the endemic of H. *pylori* infection as one of the strongest carcinogenic factors [@B8],[@B32],[@B33]. The sero-prevalence rate of H. *pylori* infection was approximately 40 to 70% in patients with gastric cancer in Asian countries [@B34], and the overall sero-prevalence rate has been decreasing with the time trend [@B8],[@B34],[@B35]. Improvements in living conditions, the water supply or sewage systems are strongly correlated with the declining prevalence of H. *pylori*[@B34]. The expansion of industrial refrigeration has reduced the need for salting and pickling for food preservation, and the development of transportation has allowed distribution of fresher products to consumers [@B3]. It has also become easy for people to include potentially protective factors such as vitamins A, C, and E in their diet throughout the year [@B9]-[@B11], which may counteract carcinogenesis in the stomach linked to intake of N-nitroso compounds in smoked or grilled meat [@B36],[@B37]. The decline in the incidence of gastric cancer in Japan has been attributed to the overall improvement of public health accompanying the high economic growth following the severe poverty after World War II. Significantly, however, our results indicate that the above factors have been particularly associated with cancer in the antrum or pylorus of the stomach, rather than with gastric cancer as a whole. The number of patients with cancer in the upper third of the stomach has, in fact, been increasing over time, and therefore it can be considered that the risk factors for adenocarcinoma in the upper third are differ from those for cancer in the lower third. In term of histopathological type that has strong association with primary site arising adenocarcinoma, the fact that the proportion of signet ring cell carcinoma has been rapidly increasing from early to middle period was not inconsistent with this sift of cancer location (Table [1](#T1){ref-type="table"}).

From a physician\'s viewpoint, the current trend suggests that in East Asian populations a larger number of patients will need to be treated for cancer in the upper third of the stomach as time passes. In addition, as the proportion of obese and elderly patients will continue to increase in the near future, treatment of gastric cancer may become more difficult than it has been in the past. In this connection, a crucial difference between Japanese and Western patients is that the incidence of adenocarcinoma at the EGJ has remained consistently low in Japan for the last 70 years. Despite the marked increase of EGJ adenocarcinoma in Western patients documented in the SEER data and previous studies, the proportion of EGJ cancer in East Asians in the SEER has remained consistently low. Considering the trends evident in the two databases, it seems unlikely that the incidence of adenocarcinoma in the EGJ will increase rapidly in East Asian countries as a result of westernization in the near future.

This large-scale database study has some limitations. First, there is the difficulty in classifying adenocarcinoma as being present in the upper third, cardia or EGJ. In general, two types of adenocarcinoma can arise in the EGJ; one is derived from the fundic glands of the stomach, and the other from Barrett\'s epithelium. These two cancers ought to be essentially distinguished from each other, i.e. upper gastric cancer with esophageal invasion, and lower esophageal cancer with gastric invasion. However, in most cases, it is clinicopathologically difficult to identify whether the origin of a neoplasm is the gastric gland or the metaplastic columnar epithelium of the esophagus. Therefore, both gastric cancer with esophageal invasion and adenocarcinoma from Barrett\'s esophagus have been registered under the same category in all clinical databases. In addition, the Japanese definition of cancer in cardia is a slightly different from that of ICD-10 (Supplemental figure [1](#SM1){ref-type="supplementary-material"}). Second, the SEER database contains no information about the lifestyle of the East Asian population, such as how long they have lived in the US or the types of foods they usually eat. Therefore, unknown or unmeasurable - but important - potential confounders might be overlooked. Another problem is that there is no guarantee that patients entered in the CIH-GCDB are a representative sample of Japanese patients with gastric cancer. The CIH-GCDB is a database representing patients seen at a single institution, although the hospital handles the highest volume of cancer patients in Japan and the registration system has been established for nearly 70 years. The multi-center national cancer database system in Japan is still in its early stages and is tightly restricted to access for general researchers. Therefore, using the CIH-GCDB was the best resource for addressing our research aims, enabling us to analyze a large number of patients over a long time period.

In conclusion, our findings suggest that cancer in the lower third of the stomach has been declining, whereas cancer in the upper third has been increasing in recent years in Japan. Unlike the situation in Western patients, currently there is no evidence of any increase of EGJ adenocarcinoma in the Japanese population. However, from a clinical viewpoint, it may become more difficult to treat gastric cancer in Japanese patients in comparison with the past, in view of the increase of elderly and obese patients presenting with adenocarcinoma in the upper third of the stomach.

Supplementary Material {#SM0}
======================
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Supplementary figure 1.

###### 

Click here for additional data file.
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:   Gastric Cancer Database at the Cancer Institute Hospital
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:   Surveillance, Epidemiology, and End Results
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:   esophago-gastric junction

ICD-O-3

:   International Classification of Diseases for Oncology, 3rd edition

JGCA

:   Japanese Gastric Cancer Association (JGCA)
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:   body mass index
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:   American Joint Committee on Cancer

![**Age-adjusted incident rate and death rate of Gastric cancer in Japan and the U.S.**A: Age-adjusted incident rate of gastric cancer on Japanese and U.S. national statistics. Citation from Cancer Registry and Statistics, Cancer Information Service, National Cancer Center in Japan [@B6] and World Health Organization, GLOBOCAN 2012[@B7]. B: Estimated number of new gastric cancer patients by gender in Japan. Citation from Cancer Registry and Statistics, Cancer Information Service, National Cancer Center in Japan [@B6]](jcav08p1935g001){#F1}

![**Primary site, patients age and BMI in CIH-GCDB.**A: Time trends of in the relative frequencies of cancers arising at each primary site, based on the CIH-GCDB data. B: Time trends in age and BMI of patients with gastric cancer by gender.](jcav08p1935g002){#F2}

![**Time trends in the relative frequencies of cancers arising at each primary site, based on the SEER database.** A: Time trend of proportional frequency for patients overall. B: Time trend of proportional frequency for Western (White or Black) patients overall. C: Time trend of proportional frequency for East Asian (Chinese, Korean and Japanese) patients](jcav08p1935g003){#F3}

###### 

Patients and tumor characteristics and the time trend in CIH-GCDB

                                           All Patients            1946 to 1974          1975 to 1994          1995 to 2014                                                  
  ------------------------- -------------- -------------- -------- -------------- ------ -------------- ------ -------------- ------- ------ -------- ------- -------- -- -- --
  (N = )                                   19,306                  5,991                 5,437                 7,878                                                         
                                           No.            \%                      No.    \%                    No.            \%             No.      \%      *p*            
  Age at treatment                                                                                                                                            \<.001         
                            Mean                          59.0                    55.1                  58.0                  62.6                                           
                            SD                            12.0                    11.1                  11.9                  11.6                                           
  Gender                                                                                                                                                      0.029          
                            Male                          12,584   65.2                  3,827          63.9                  3,599   66.2            5,158   65.5           
                            Female                        6,702    34.7                  2,164          36.1                  1,838   33.8            2,700   34.3           
  BMI (kg/m^2^)                                                                                                                                                              
  Mean                                     21.3                    19.8                  21.5                  22.3                                                          
  SD                                       3.2                     2.8                   2.9                   3.3                                                           
  Primary site\*                                                                                                                                              \<.001         
                            EGJ                           1,160    6.0                   457            7.6                   351     6.5             352     4.5            
                            Upper                         2,571    13.3                  401            6.7                   762     14.0            1,388   17.6           
                            Middle                        8,229    42.6                  2,102          35.1                  2,621   48.2            3,506   44.5           
                            Lower                         6,843    35.4                  2,927          48.9                  1,565   28.8            2,351   29.8           
                            Unclassified                  503      2.6                   104            1.7                   138     2.5             281     3.6            
  Tumor size (mm)                                                                                                                                             \<.001         
                            Mean                          56.4                    68.8                  55.3                  48.5                                           
                            SD                            35.9                    29.4                  38.6                  35.6                                           
  Stage                                                                                                                                                       \<.001         
                            IA                            6,225    32.2                  714            11.9                  2,080   38.3            3,431   43.6           
                            IB                            1,483    7.7                   283            4.7                   451     8.3             749     9.5            
                            IIA                           1,466    7.6                   563            9.4                   353     6.5             550     7.0            
                            IIB                           1,557    8.1                   630            10.5                  416     7.7             511     6.5            
                            IIIA                          1,390    7.2                   691            11.5                  308     5.7             391     5.0            
                            IIIB                          1,428    7.4                   699            11.7                  356     6.5             373     4.7            
                            IIIC                          1,108    5.7                   498            8.3                   352     6.5             258     3.3            
                            IV                            3,072    15.9                  1,304          21.8                  754     13.9            1,014   12.9           
                            Unknown                       1,577    8.2                   609            10.2                  367     6.8             601     7.6            
  Histological findings\*                                                                                                                    \<.001                          
                            tub/pap                       7,989    41.4                  2,650          44.2                  2,284   42.0            3,055   38.8           
                            poor                          5,797    30.0                  1,980          33.0                  1,476   27.1            2,341   29.7           
                            muc                           482      2.5                   182            3.0                   133     2.4             167     2.1            
                            sig                           3,299    17.1                  361            6.0                   1,292   23.8            1,646   20.9           
                            Unknown                       32       0.2                   6              0.1                   2       0.0             24      0.3            
                                                                                                                                                                             

BMI; Body Mass Index, SD: Standard Deviation, EGJ: Esophago-gastric Junction,

\*; Descriptions according to the definition by Japanese Gastric Cancer Association

###### 

Independent risk factors for upper third gastric cancer in CIH-GCDB

                                   Odds Ratio   SE      P-value   95% Confidential Interval        
  -------------------------------- ------------ ------- --------- --------------------------- ---- -------
  **Gender (Male/Female)**         0.745        0.036   \<0.001   0.678                       \-   0.818
  **Time proceeds (per year)**     1.019        0.016   \<0.001   1.158                       \-   1.222
  **Upper age (every 10 years)**   1.082        0.020   \<0.001   1.043                       \-   1.122
  **Higher BMI(kg/m2)**            1.036        0.007   \<0.001   1.022                       \-   1.050

BMI; Body Mass Index

###### 

Patients and tumor characteristic of All Patients and East Asian patients with gastric cancer in SEER database

                                                                                        All Patients             East Asian               
  ----------------------------------------------------------- ------------------------- -------------- --------- ------------ ----------- ---------
                                                              **(N = )**                **78,625**     **(%)**                **7,202**   **(%)**
  **Diagnostic Year**                                                                                                                     
                                                              **1973-1982**             18,875         24.0                   1,232       17.1
                                                              **1983-1992**             19,847         25.2                   1,793       24.9
                                                              **1993-2002**             19,852         25.2                   2,123       29.5
                                                              **2003-2012**             20,051         25.5                   2,054       28.5
  **Race**                                                    **White**                 58,118         73.9                   *N.A.*      
                                                              **Black**                 9,251          11.8                               
                                                              **East Asian**            7,202          9.2                                
                                                              **Others**                4,054          5.2                                
  **Age at diagnosis (Year)**                                                                                                             
                                                              **Mean**                  69.4                     70.5                     
                                                              **SD**                    15.7                     13.5                     
  **Gender**                                                                                                                              
                                                              **Male**                  48,541         61.7                   4,241       58.9
                                                              **Female**                30,084         38.3                   2,961       41.1
  **Primary Site**                                                                                                                        
                                                              **Cardia**                18,496         23.5                   673         9.3
                                                              **Fundus**                3,270          4.2                    189         2.6
                                                              **Body**                  5,268          6.7                    767         10.6
                                                              **Pylorus or Antrum**     16,490         21.0                   2,361       32.8
                                                              **Overlapping**           17,380         22.1                   2,061       28.6
                                                              **NOS**                   17,721         22.5                   1,151       16.0
  **Tumor size (mm)**                                                                                                                     
                                                              **Mean**                  48.3                     49.5                     
                                                              **SD**                    44.8                     43.7                     
  **Histological findings**                                                                                                               
                                                              **well differentiated**   3,851          4.9                    308         4.3
                                                              **moderate**              14,933         19.0                   1,499       20.8
                                                              **poor**                  33,644         42.8                   3,494       48.5
                                                              **others**                2,922          3.7                    158         2.2
                                                              **Unknown**               23,275         29.6                   1,748       24.3
  **TNM Stage AJCC 6th (Available data from 2004 to 2012)**                                                                               
                                                              **(N = )**                18,092         (%)                    1,840       (%)
                                                              **0**                     182            1.0                    27          1.5
                                                              **IA**                    2,530          14.0                   311         16.9
                                                              **IB**                    1,713          9.5                    198         10.8
                                                              **II**                    1,899          10.5                   194         10.5
                                                              **IIIA**                  1,460          8.1                    156         8.5
                                                              **IIIB**                  324            1.8                    46          2.5
                                                              **IV**                    6,760          37.4                   668         36.3
                                                              **Unknown**               3,224          17.8                   240         13.0

SD; Standard deviation, NOS; Not otherwise specified
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